Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Incannex Healthcare Limited Sponsored ADR ( (IXHL) ) has provided an announcement.
On January 22, 2026, Incannex Healthcare announced it has formed a Clinical Advisory Board to guide the ongoing development of PSX-001, its synthetic psilocybin program for generalized anxiety disorder, as it moves into its next clinical and regulatory phase. The board brings together leading experts in psychiatry, neurobiology and psychopharmacology, including C. Neill Epperson, Charles B. Nemeroff and Alan F. Schatzberg, and is expected to strengthen trial design, endpoint selection, regulatory strategy and overall execution for PSX-001, underscoring the company’s push to enhance scientific rigor, manage development risk and support long-term value creation as it advances a key asset in a therapeutic area with significant unmet need.
The most recent analyst rating on (IXHL) stock is a Hold with a $0.38 price target. To see the full list of analyst forecasts on Incannex Healthcare Limited Sponsored ADR stock, see the IXHL Stock Forecast page.
Spark’s Take on IXHL Stock
According to Spark, TipRanks’ AI Analyst, IXHL is a Neutral.
The score is held down primarily by weak financial performance (large losses and negative free cash flow) and limited valuation support (negative P/E, no dividend). Technicals are broadly neutral with slightly negative MACD and high volatility risk. Offsetting these, corporate events are a relative positive due to Fast Track designation and favorable clinical/program milestones.
To see Spark’s full report on IXHL stock, click here.
More about Incannex Healthcare Limited Sponsored ADR
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company focused on developing innovative fixed-dose combination medicines targeting chronic conditions with limited or inadequate treatment options, including obstructive sleep apnea, rheumatoid arthritis and generalized anxiety disorder. Its lead programs include IHL-42X, an oral combination of dronabinol and acetazolamide for obstructive sleep apnea; IHL-675A, an oral combination of cannabidiol and hydroxychloroquine sulfate for inflammatory conditions such as rheumatoid arthritis; and PSX-001, an oral synthetic psilocybin candidate approved for Phase 2 development in generalized anxiety disorder.
Average Trading Volume: 17,677,695
Technical Sentiment Signal: Sell
Current Market Cap: $123.6M
Find detailed analytics on IXHL stock on TipRanks’ Stock Analysis page.